Publicacións nas que colabora con Francisco Barros Angueira (7)

2020

  1. Efficacy and toxicity of adjuvant chemotherapy on colorectal cancer patients: how much influence from the genetics?

    Journal of Chemotherapy, pp. 1-13

2019

  1. Association of GSTP1 and ERCC1 polymorphisms with toxicity in locally advanced head and neck cancer platinum-based chemoradiotherapy treatment

    Head and Neck, Vol. 41, Núm. 8, pp. 2704-2715

2015

  1. Long Survival and Severe Toxicity under 5-Fluorouracil-Based Therapy in a Patient with Colorectal Cancer Who Harbors a Germline Codon-Stop Mutation in TYMS

    Mayo Clinic Proceedings, Vol. 90, Núm. 9, pp. 1298-1303

2012

  1. The value of genetic polymorphisms to predict toxicity in metastatic colorectal patients with irinotecan-based regimens

    Cancer Chemotherapy and Pharmacology, Vol. 69, Núm. 6, pp. 1591-1599

  2. X-ray cross-complementing group 1 and thymidylate synthase polymorphisms might predict response to chemoradiotherapy in rectal cancer patients

    International Journal of Radiation Oncology Biology Physics, Vol. 82, Núm. 1, pp. 138-144

2011

  1. Use of a comprehensive panel of biomarkers to predict response to a fluorouracil-oxaliplatin regimen in patients with metastatic colorectal cancer

    Pharmacogenomics, Vol. 12, Núm. 3, pp. 433-442

2010

  1. Pharmacogenetic analysis in neoadjuvant chemoradiation for rectal cancer: High incidence of somatic mutations and their relation with response

    Pharmacogenomics, Vol. 11, Núm. 6, pp. 747-761